Chemotherapy Induced Pathologic Complete Response in Malignant Pleural Mesothelioma A Review and Case Report

被引:13
作者
Bech, Cecilia [1 ]
Sorensen, Jens Benn [1 ]
机构
[1] Natl Univ Hosp, Finsen Ctr, Dept Oncol, DK-2100 Copenhagen, Denmark
关键词
Malignant pleural mesothelioma; Complete response; Clinically complete response; Pathologically complete response; CR; cCR; pCR; RANDOMIZED PHASE-III; EXTRAPLEURAL PNEUMONECTOMY; CISPLATIN;
D O I
10.1097/JTO.0b013e3181d86ea9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Malignant pleural mesothelioma is a rare aggressive disease with a poor prognosis and usually modest responses to chemotherapy. Complete responses (CRs) to chemotherapy are rare. Evaluation is usually based on radiology, and CR is therefore clinical CR (cCR) and whether this indicates absence of viable tumor cells is unknown. We have observed two cases of CR which at subsequent surgery were histologically verified, thus being pathologic CRs (pCRs). pCR after chemotherapy is thus possible but rare, and we here present the cases from our institution together with a review on the literature available on the subject. Methods: A literature search using relevant keywords was performed in PubMed and MedLine. Results: A larger number of reports on cCR but only five reports on pCR were identified. All published cases of pCR, 16 patients in five trials, are presented and discussed, and larger trials reporting cCR are mentioned. pCR did not in all cases correspond to cCR. The cases having pCR identified all had the epithelial or unknown subtype, and all had early-stage disease before treatment. Conclusion: pCR is possible but rare, and a pCR does not always require a cCR. So far reported cases of pCR have all had the epithelial or unknown subtype and pretreatment stages have been low. The cases in our institution also had epithelial subtype but had stage III disease, and it thus seems possible to obtain a pCR despite a larger tumor burden.
引用
收藏
页码:735 / 740
页数:6
相关论文
共 20 条
  • [1] Astoul P, 1998, CANCER, V83, P2099, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO
  • [2] 2-3
  • [3] INTRAPLEURAL RECOMBINANT IL-2 IN PASSIVE IMMUNOTHERAPY FOR MALIGNANT PLEURAL EFFUSION
    ASTOUL, P
    VIALLAT, JR
    LAURENT, JC
    BRANDELY, M
    BOUTIN, C
    [J]. CHEST, 1993, 103 (01) : 209 - 213
  • [4] Symptoms and patient-reported well-being: Do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma
    Bottomley, Andrew
    Coens, Corneel
    Efficace, Fabio
    Gaafar, Rabab
    Manegold, Christian
    Burgers, Sjaak
    Vincent, Mark
    Legrand, Catherine
    van Meerbeeck, Jan P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (36) : 5770 - 5776
  • [5] BOUTIN C, 1994, CANCER, V74, P2460, DOI 10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO
  • [6] 2-N
  • [7] PLEUROPNEUMONECTOMY IN MANAGEMENT OF DIFFUSE MALIGNANT MESOTHELIOMA OF PLEURA - EXPERIENCE WITH 29 PATIENTS
    BUTCHART, EG
    ASHCROFT, T
    BARNSLEY, WC
    HOLDEN, MP
    [J]. THORAX, 1976, 31 (01) : 15 - 24
  • [8] DONG MS, 1995, CANCER, V76, P2230, DOI 10.1002/1097-0142(19951201)76:11<2230::AID-CNCR2820761108>3.0.CO
  • [9] 2-2
  • [10] Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials
    Fennell, DA
    Parmar, A
    Shamash, J
    Evans, MT
    Sheaff, MT
    Sylvester, R
    Dhaliwal, K
    Gower, N
    Steele, J
    Rudd, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) : 184 - 189